** Shares of Mirum Pharmaceuticals rise 5.7% to $43.97
** Co raises 2024 rev. forecast to the range of $330 mln to $335 mln from its prior range of $310 mln to $320 mln
** Posts Q3 rev. of $90.3 mln, above analysts' est. of $82.0 mln - LSEG
** Reports Q3 loss per share of 30 cents, smaller than analysts' est. of 45 cents - LSEG
** Co's Livmarli, a liver disease drug, posts Q3 rev. of $59.1 mln, above analysts' est of $50 mln - LSEG
** All 11 brokerages covering MIRM rate the stock "buy" or higher; median PT is $65.50 - LSEG
** Stock has risen ~49% YTD, including session gains
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。